The Medicines Manufacturing Industry Partnership (MMIP) represents the voice of medicines manufacturers in the UK. It was established jointly by Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class, advanced centre for medicines manufacturing.
The UK's medicine industry is one of the country's leading manufacturing sectors, with exports worth over £20bn. The Partnership wants to ensure that the UK continues to be an attractive place for this high-value industry to secure exports, provide high skilled job opportunities and contribute to solving the country's productivity puzzle.
Outgoing Chair of the Medicines Manufacturing Industrial Partnership Ian McCubbin speaks to the ABPI Annual Conference 2017 on 'Advanced Therapies and Complex Medicines Manufacturing... a UK opportunity'
Working closely with key government organisations including the Medicines and Healthcare products Regulatory Authority (MHRA), UK Trade and Investment (UKTI), Innovate UK and the Office for Life Sciences (OLS), MMIP is examining the UK's position in medicines manufacturing and identifying opportunities for improvement.
The MMIP is divided into five workstreams. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice.
These workstreams are:
The MMIP also works to build the medicines manufacturing community.
MMIP is supported by the ABPI, the BioIndustry Association (BIA) and the Knowledge Transfer Network, and includes leadership from Allergan Biologics, AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron. It has a senior project director, employed by the ABPI, and additional dedicated resources provided by partners.
For more information please contact the MMIP Operations Team:
You can keep up to date via our Twitter hashtag #MMIP, by following tweets from @ABPI_UK or @BIA_UK. The MMIP LinkedIn group is an opportunity for the medicines manufacturing community to connect and network with the MMIP.
The regulatory environment workstream is trying to maximise innovative processes by highlighting existing regulatory flexibility and the positive UK regulatory landscape to industry.
As part of its programme of work, the Medicines Manufacturing Industry Partnership (MMIP) seeks to ensure that the UK has an adaptive workforce with relevant skills to sustain the future requirements of the UK medicines manufacturing industry.
The supply chain workstream seeks to deliver capable and connected infrastructure, building understanding of medicines manufacturing supply chains, identifying opportunities to maximise supply and fostering non-competitive sector collaboration.
The technology workstream seeks to understand and pursue the future needs of the medicines manufacturing industry.
The Knowledge Transfer Network (KTN) have created a tool which aims to provide a visual dynamic representation of the UK Medicines Manufacturing Innovation Landscape.